High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy
Laura Lupini(University of Ferrara), Massimo Negrini(University of Ferrara), Patrizia Querzoli(University of Ferrara), Alessio Schirone, Antonio Frassoldati(Italian Oncology Group of Clinical Research), Massimo Pedriali(University of Ferrara), A. Moretti(University of Ferrara), Roberta Roncarati(Institute of Genetic and Biomedical Research), Cristian Bassi(University of Ferrara)
Cited by 23
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
|Annals of Oncology|2012|339
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy
|Cancer Research|2010|244
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240